Source comparison
TB-500 Animal vs Human Research: The Comparison
Wound Healing Multiple RCTs in rodents showing 40–60% faster closure; histology confirms increased collagen deposition and reduced scar formation Zero published controlled trials; anecdotal reports only Mechanism is biologically plausible in humans but dosing,
This comparison does not assign a generated winner or score.
- Wound Healing
- Multiple RCTs in rodents showing 40–60% faster closure; histology confirms increased collagen deposition and reduced scar formation
- Zero published controlled trials; anecdotal reports only
- Mechanism is biologically plausible in humans but dosing, timeline, and effect size are extrapolated, not validated
- Tendon/Ligament Repair
- Equine studies show 30–35% faster ultrasonographic resolution of tendon lesions; reduced inflammatory markers in synovial fluid
- No human trials; case reports from athletes lack controls or objective imaging follow-up
- Animal models used (horses) have tendon structure and healing timelines more similar to humans than rodents, but load-bearing differences remain
- Cardiac Ischaemia
- Rodent studies demonstrate 35–40% infarct size reduction; increased capillary density post-MI
- No human cardiac trials published; no FDA approval for cardiovascular indication
- Promising preclinical data but cardiac repair in humans involves different immune, fibrotic, and remodelling processes than in mice
- Anti-Inflammatory Effects
- Reduced IL-6, TNF-α, and NF-κB signalling in multiple animal inflammation models
- No controlled human inflammation studies; no published cytokine profiling in TB-500 users
- Mechanism is sound but human dosing to achieve therapeutic tissue concentrations is unknown
- Safety/Tolerability
- Well-tolerated in animal studies up to 16 weeks; no serious adverse events reported in published trials
- No long-term human safety data; no Phase I dose-escalation trials to establish maximum tolerated dose or pharmacokinetics
- Absence of human safety trials means long-term risks, drug interactions, and population-specific contraindications are undefined